学术论文写作规范与投.ppt
《学术论文写作规范与投.ppt》由会员分享,可在线阅读,更多相关《学术论文写作规范与投.ppt(87页珍藏版)》请在淘文阁 - 分享文档赚钱的网站上搜索。
1、学术论文写作规范与投稿学术论文写作规范与投稿文 阳主要内容主要内容一、学术论文的格式要求二、三大检索系统简介三、提高论文被三大检索系统收录的投稿策略一、学术论文的格式一、学术论文的格式概念概念:n n学术论文:是某一学术课题在实验性、理论性或学术论文:是某一学术课题在实验性、理论性或观测性上具有新的科学研究成果或创新见解和知观测性上具有新的科学研究成果或创新见解和知识的科学记录;或是某种已知原理应用于实际中识的科学记录;或是某种已知原理应用于实际中取得新进展的科学总结,用以提供学术会议上宣取得新进展的科学总结,用以提供学术会议上宣读、交流或讨论;或在学术刊物上发表;或作其读、交流或讨论;或在学
2、术刊物上发表;或作其他用途的书面文件。他用途的书面文件。n n学术论文应提供新的科技信息,其内容应有所发学术论文应提供新的科技信息,其内容应有所发现、有所发明、有所创造、有所前进,而不是重现、有所发明、有所创造、有所前进,而不是重复、模仿、抄袭前人的工作。复、模仿、抄袭前人的工作。论文的结构论文的结构:n n论文标题论文标题n n作者署名及其工作单位作者署名及其工作单位n n摘要摘要+关键词关键词n n引言引言(Introduction)(Introduction)n n材料与方法材料与方法(Materials and methods)(Materials and methods)n n结果结
3、果(Results)(Results)n n讨论与结论讨论与结论(Discussion&Conclusion)(Discussion&Conclusion)n n致谢致谢n n参考文献参考文献 论文格式论文格式/标题(标题(TitleTitle)n n标题:是学术论文内容的高度概括,是反映论文中最重要特定内容的逻辑组合。应该准确、简洁和清晰地反映文章内容和中心论题,以便读者选读和检索。英文标题要求:英文标题要求:1、根据国际标准化组织规定,专业论文每条标题不要超过1012个英文单词,如果10个单词不足以概括全文的内容,可使用副标题(眉题)来加以说明;2、标题中一般不用缩略语,广为人知的、已得到
4、公认的除外;3、标题中通常不用介词短语,但可以用由on引导的短语英文标题要求:英文标题要求:4 4、标题中用的最多的是名词、名词短语,包括动名、标题中用的最多的是名词、名词短语,包括动名词;词;例如例如 Title:Processing of X-ray diffraction data Title:Processing of X-ray diffraction data collected in oscillation mode collected in oscillation mode(震荡模式中震荡模式中X X射线衍射线衍射数据的分析方法)射数据的分析方法)Author(s):Otwin
5、owski Z,Minor W Author(s):Otwinowski Z,Minor W Source:MACROMOLECULAR CRYSTALLOGRAPHY,PT A Source:MACROMOLECULAR CRYSTALLOGRAPHY,PT A METHODS IN ENZYMOLOGY 276:307-326 1997 METHODS IN ENZYMOLOGY 276:307-326 1997 酶学方法酶学方法美国美国 Elsevier Elsevier SCI SCI被引被引1293912939次,次,该题名堪称准确、简洁、清楚的典范,该题名堪称准确、简洁、清楚的典范
6、,即即用用7 7个实词和个实词和2 2个虚词清晰地说明了论文的研究主题内容个虚词清晰地说明了论文的研究主题内容为为Processing,Processing,对象是对象是X-ray diffraction data X-ray diffraction data collected in oscillation mode.collected in oscillation mode.英文标题要求:英文标题要求:5 5、标题中的字母大写也有一定的规律:、标题中的字母大写也有一定的规律:n n第一个词的首字母大写,本来就必须大写的专有第一个词的首字母大写,本来就必须大写的专有名词的首字母大写,其余不大
7、写;名词的首字母大写,其余不大写;n n所有实词的首字母大写,冠词和五个字母以下的所有实词的首字母大写,冠词和五个字母以下的介词、连词的首字母不大写;介词、连词的首字母不大写;n n对于标题用全部字母大写的方法,一般不采取,对于标题用全部字母大写的方法,一般不采取,因为这种形式不易辨认。因为这种形式不易辨认。6 6、标题中尽可能不用标点符号,如果有,也就是冒、标题中尽可能不用标点符号,如果有,也就是冒号号(colon)(colon)或者破折号或者破折号(dash)(dash)。论文格式论文格式/作者署名及其工作单位作者署名及其工作单位n n是为了表明文责自负n n是记录作者的劳动成果n n是便
8、于读者与作者的联系及文献检索(作者索引)论文格式论文格式/摘要(摘要(AbstractAbstract)n n摘要是从整篇文章摘录出来的要点,是对研究目的、方法和结果的全面概括和总结,是全文内容的浓缩。n n内容要求:逻辑性强、完整n n语言要求:简练、准确、自然论文格式论文格式/摘要(摘要(AbstractAbstract)根据内容的不同,摘要可分为以下三大类:根据内容的不同,摘要可分为以下三大类:1 1、报道性(信息性)摘要:是信息量最大的摘要,比、报道性(信息性)摘要:是信息量最大的摘要,比较完整地报道原文章中的具体内容,尤其是研究结果、较完整地报道原文章中的具体内容,尤其是研究结果、结
9、论等方面的内容。结论等方面的内容。报道性(信息性)摘要适用于研究性和专题论文报道性(信息性)摘要适用于研究性和专题论文2 2、指示性摘要也就是介绍性摘要,又称陈述性摘要。、指示性摘要也就是介绍性摘要,又称陈述性摘要。主要向读者介绍文章的主要内容和问题,但不涉及具主要向读者介绍文章的主要内容和问题,但不涉及具体的方法、研究结果。体的方法、研究结果。3 3、报道、报道-指示性摘要:是以报道性摘要的形式表述论文指示性摘要:是以报道性摘要的形式表述论文中价值最高的那部分内容,其余部分则以指示性摘要中价值最高的那部分内容,其余部分则以指示性摘要形式表达。形式表达。论文格式论文格式/摘要(摘要(Abstr
10、actAbstract)n n2020世纪世纪8080年代中期出现了另一种摘要文体,即年代中期出现了另一种摘要文体,即“结构结构式摘要式摘要(structured abstract),(structured abstract),该摘要实质上是报该摘要实质上是报道性摘要的结构化表达。道性摘要的结构化表达。(1)(1)目的目的(Objective):(Objective):研究的问题、目的或设想等研究的问题、目的或设想等;(2)(2)设计设计(Design):(Design):研究的基本设计研究的基本设计,样本的选择样本的选择;(3)(3)单位单位(Setting):(Setting):开展研究的
11、单位开展研究的单位;(4)(4)对对象象(Patients,(Patients,Participants):Participants):研研究究对对象象的的信信息息;(5)(5)处置处置(Interventions):(Interventions):处置方法处置方法;(6)(6)主主要要结结果果测测定定(Main(Main Outcome Outcome Measures):Measures):实实验验过程过程;(7)(7)结果结果(Results):(Results):研究的主要发现研究的主要发现;(8)(8)结论结论(Conclusions):(Conclusions):主要结论及其潜在应
12、用主要结论及其潜在应用SCI论文结构式摘要案例n nAbstract:Abstract:Abstract:Abstract:ContextContextContextContext Patients experience the highest rate of death and Patients experience the highest rate of death and recurrent ischemic events during the early period after an acute coronary recurrent ischemic events during th
13、e early period after an acute coronary syndrome,but it is not known whether early initiation of treatment with a syndrome,but it is not known whether early initiation of treatment with a statin can reduce the occurrence of these early events.statin can reduce the occurrence of these early events.n n
14、Objective Objective Objective Objective To determine whether treatment with atorvastatin,80 mg/d,To determine whether treatment with atorvastatin,80 mg/d,initiated 24 to 96 hours after an acute coronary syndrome,reduces death and initiated 24 to 96 hours after an acute coronary syndrome,reduces deat
15、h and nonfatal ischemic events.nonfatal ischemic events.n nDesign and SettingDesign and SettingDesign and SettingDesign and Setting A randomized,double-blind trial conducted from May 1997 A randomized,double-blind trial conducted from May 1997 to September 1999,with follow-up through 16 weeks at 122
16、 clinical centers to September 1999,with follow-up through 16 weeks at 122 clinical centers in Europe,North America,South Africa,and Australasia.in Europe,North America,South Africa,and Australasia.n nPatients Patients Patients Patients A total of 3086 adults aged 18 years or older with unstable ang
17、ina A total of 3086 adults aged 18 years or older with unstable angina or non-Q-wave acute myocardial infarction.or non-Q-wave acute myocardial infarction.n nInterventions Interventions Interventions Interventions Patients were stratified by center and randomly assigned to Patients were stratified b
18、y center and randomly assigned to receive treatment with atorvastatin(80 mg/d)or matching placebo between 24 receive treatment with atorvastatin(80 mg/d)or matching placebo between 24 and 96 hours after hospital admission.and 96 hours after hospital admission.n nMain OutcomeMain OutcomeMain OutcomeM
19、ain Outcome Measures Measures Measures Measures Primary end point event defined as death,nonfatal Primary end point event defined as death,nonfatal acute myocardial infarction,cardiac arrest with resuscitation,or recurrent acute myocardial infarction,cardiac arrest with resuscitation,or recurrent sy
20、mptomatic myocardial ischemia with objective evidence and requiring symptomatic myocardial ischemia with objective evidence and requiring emergency rehospitalization.emergency rehospitalization.n nResultsResultsResultsResults A primary end point event occurred in 228 patients(14.8%)in the A primary
21、end point event occurred in 228 patients(14.8%)in the atorvastatin group and 269 patients(17.4%)in the placebo group(relative atorvastatin group and 269 patients(17.4%)in the placebo group(relative risk RR,0.84;95%confidence interval CI,0.70-1.00;P=.048).There risk RR,0.84;95%confidence interval CI,
22、0.70-1.00;P=.048).There were no significant differences in risk of death,nonfatal myocardial were no significant differences in risk of death,nonfatal myocardial infarction,or cardiac arrest between the atorvastatin group and the placebo infarction,or cardiac arrest between the atorvastatin group an
23、d the placebo group,although the atorvastatin group had a lower risk of symptomatic group,although the atorvastatin group had a lower risk of symptomatic ischemia with objective evidence and requiring emergency rehospitalization ischemia with objective evidence and requiring emergency rehospitalizat
24、ion(6.2%vs 8.4%;RR,0.74;95%CI,0.57-0.95;P=.02).Likewise,there were(6.2%vs 8.4%;RR,0.74;95%CI,0.57-0.95;P=.02).Likewise,there were no significant differences between the atorvastatin group and the placebo no significant differences between the atorvastatin group and the placebo group in the incidence
25、 of secondary outcomes of coronary revascularization group in the incidence of secondary outcomes of coronary revascularization procedures,worsening heart failure,or worsening angina,although there procedures,worsening heart failure,or worsening angina,although there were fewer strokes in the atorva
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- 学术论文 写作 规范
限制150内